The 36-month beta value for CLDX is at 1.14. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CLDX is 64.51M, and currently, shorts hold a 14.15% of that float. The average trading volume for CLDX on June 04, 2025 was 844.79K shares.
CLDX) stock’s latest price update
The stock of Celldex Therapeutics Inc (NASDAQ: CLDX) has decreased by -0.50 when compared to last closing price of 19.97.Despite this, the company has seen a gain of 0.46% in its stock price over the last five trading days. zacks.com reported 2025-05-08 that Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago.
CLDX’s Market Performance
CLDX’s stock has risen by 0.46% in the past week, with a monthly drop of -3.82% and a quarterly drop of -0.65%. The volatility ratio for the week is 3.11% while the volatility levels for the last 30 days are 4.62% for Celldex Therapeutics Inc The simple moving average for the last 20 days is 0.76% for CLDX’s stock, with a simple moving average of -23.11% for the last 200 days.
Analysts’ Opinion of CLDX
Many brokerage firms have already submitted their reports for CLDX stocks, with Canaccord Genuity repeating the rating for CLDX by listing it as a “Buy.” The predicted price for CLDX in the upcoming period, according to Canaccord Genuity is $64 based on the research report published on April 28, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $46. The rating they have provided for CLDX stocks is “Overweight” according to the report published on March 20th, 2025.
UBS gave a rating of “Buy” to CLDX, setting the target price at $44 in the report published on February 13th of the current year.
CLDX Trading at 4.13% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.72% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDX starting from Marucci Anthony S, who purchase 11,500 shares at the price of $26.82 back on Nov 11 ’24. After this action, Marucci Anthony S now owns 40,284 shares of Celldex Therapeutics Inc, valued at $308,430 using the latest closing price.
Martin Samuel Bates, the SVP AND CFO of Celldex Therapeutics Inc, sale 17,172 shares at $35.42 during a trade that took place back on Jun 14 ’24, which means that Martin Samuel Bates is holding 28,125 shares at $608,315 based on the most recent closing price.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -28.74 for the present operating margin
- 0.79 for the gross margin
The net margin for Celldex Therapeutics Inc stands at -23.66. The total capital return value is set at -0.31. Equity return is now at value -23.20, with -22.24 for asset returns.
Based on Celldex Therapeutics Inc (CLDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -50.03.
Currently, EBITDA for the company is -191.9 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 172.71. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.67.
Conclusion
In conclusion, Celldex Therapeutics Inc (CLDX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
